Xue et al. (19) used LDRT combined with SBRT in the iRT modality for advanced treatment-naïve PD-L1-positive NSCLC, with a confirmed ORR (confirmed ORR) of 57.1% and a median PFS of 8.6 months, which was safe and tolerable. The gene discussed is CD274; the disease is non-small cell lung carcinoma.